A5070632466- Immune cells in cancer
- Cancer, Hypoxia, and Metabolism
- Circular RNAs in diseases
- Angiogenesis and VEGF in Cancer
- Ubiquitin and proteasome pathways
- Cancer Immunotherapy and Biomarkers
- MicroRNA in disease regulation
- RNA modifications and cancer
Jiangsu Province Hospital
2022-2025
Nanjing Medical University
2022-2025
Chinese Academy of Medical Sciences & Peking Union Medical College
2022-2025
Abstract Programmed death receptor-1 (PD-1) blockade have achieved some efficacy but only in a fraction of patients with hepatocellular carcinoma (HCC). cell 1 ligand (PD-L1) binds to its receptor PD1 on T cells dampen antigen-tumor immune responses. However, the mechanisms underlying PD-L1 regulation are not fully elucidated. Herein, we identify that tumoral Prdm1 overexpression inhibits growth immune-deficient mouse models. Further, upregulates levels, dampening anti-tumor immunity vivo,...
Abstract Mounting research indicates that circRNAs are pivotal elements in tumorigenesis and progression. Understanding the mechanisms by which function tumors is crucial for identifying undiscovered diagnostic treatment targets. This centers on unraveling novel circRNA, circFADS1, influences hepatocellular carcinoma (HCC) CircFADS1 shows elevated expression HCC linked to unfavorable prognosis. Functionally, circFADS1 overexpression accelerates progression through inducing proliferation...